№ lp_1_2_23194
Alectinib is a medication for adjuvant treatment in adult patients with resected ALK-positive non-small cell lung cancer (NSCLC), seeking to improve disease-free survival compared to platinum-based chemotherapy.
Year: 2024
Region / city: Australia
Topic: Pharmacological treatment
Document type: Pharmaceutical submission
Agency / institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Unknown
Target audience: Medical practitioners, healthcare professionals
Period of validity: Not specified
Approval date: 23 December 2024
Date of amendments: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.